论文部分内容阅读
目的观察阿托伐他汀治疗2型糖尿病高脂血症的疗效及安全性。方法 2型糖尿病并高脂血症患者286例随机分为对照组142例与治疗组144例。对照组给予辛伐他汀10mg/次,1次/d,每晚口服;治疗组给予阿托伐他汀10mg/次,1次/d,每晚口服。2组疗程均为12周,比较2组治疗前、后总胆固醇(total cholesterol,TC)、三酰甘油(triacylglycerol,TG)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)、高密度脂蛋白胆固醇(highdensity lipoprotein-cholesterol,HDL-C)水平。结果 2组治疗后TG,TC,LDL-C水平较治疗前下降(P<0.05),治疗组下降优于对照组(P<0.05);治疗组治疗后HDL-C水平较治疗前增高(P<0.05),对照组治疗前、后HDL-C水平比较差异无统计学意义(P>0.05);治疗组不良反应发生率低于对照组(P<0.05)。结论阿托伐他汀治疗糖尿病高脂血症疗效优于辛伐他汀,且不良反应轻。
Objective To observe the efficacy and safety of atorvastatin in type 2 diabetic patients with hyperlipidemia. Methods 286 patients with type 2 diabetes mellitus and hyperlipidemia were randomly divided into control group (n = 142) and treatment group (n = 144). Control group was given simvastatin 10mg / time, 1 time / d, every night oral; treatment group was given atorvastatin 10mg / time, 1 / d, every night oral. The two groups were treated for 12 weeks. The total cholesterol (TC), triacylglycerol (TG), low density lipoprotein-cholesterol (LDL-C) High-density lipoprotein-cholesterol (HDL-C) levels. Results The levels of TG, TC and LDL-C in the two groups after treatment were significantly lower than those before treatment (P <0.05), and those in the treatment group were better than those in the control group (P <0.05). The levels of HDL-C in the treatment group were significantly higher than those before treatment <0.05). The levels of HDL-C in the control group before and after treatment had no significant difference (P> 0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group (P <0.05). Conclusions Atorvastatin is superior to simvastatin in the treatment of diabetic hyperlipidemia with mild adverse reactions.